BWPT-301 data

Results from a Phase II trial showed that patients on BWPT-301 had reduction in diarrhea, wasting, and malabsorption, the company said. The drug was well-tolerated.

In the dose-escalating, open-label trial, 6 patients were given 3 g/kg/day of BWPT-301 for 10 days via a nasogastric feeding tube. At the end of the study, all patients chose to continue oral dosing for the next six months. ...